Information Provided By: 
Fly News Breaks for July 29, 2019
ALKS
Jul 29, 2019 | 14:09 EDT
Stifel analyst Paul Matteis called Alkermes' settlement with patent challenger Amneal Pharma "a nice win" that removes an overhang on the stock, but "not thesis changing." The analyst, who thinks remaining questions about the near-to-mid term performance of Vivitrol and Aristada and the launch of ALKS3831 will be the primary factors in how the stock trades in the next 12-18 months, keeps a Hold rating on Alkermes shares.
News For ALKS From the Last 2 Days
